AVEO Pharmaceuticals, Inc. (AVEO) financial statements (2022 and earlier)

Company profile

Business Address 30 WINTER STREET
BOSTON, MA 02108
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:87,32961,76147,74524,42633,52923,34834,135
Cash and cash equivalents70,54261,76129,78524,42714,94915,09626,634
Short-term investments16,784 35,920 18,5768,2527,501
Other undisclosed cash, cash equivalents, and short-term investments3 (17,960)(1)4  
Receivables9,8111,1971,6313,0264021,0274,641
Inventory, net of allowances, customer advances and progress billings1,656      
Inventory1,656      
Other undisclosed current assets5,9402,5501,22448316,2521,9401,600
Total current assets:104,73665,50850,60027,93550,18326,31540,376
Noncurrent Assets
Operating lease, right-of-use asset178903 
Property, plant and equipment276343    23
Other noncurrent assets151158  1530143
Other undisclosed noncurrent assets     940 
Total noncurrent assets:6051,404  15970166
TOTAL ASSETS:105,34166,91250,60027,93550,19827,28540,542
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities13,0967,8433,8026,1974,8943,7175,531
Accounts payable2,7123,3801,4663,4992,4362,1861,425
Accrued liabilities5,4214,4632,3362,6982,4581,5314,106
Employee-related liabilities4,963      
Deferred revenue5781,9741,974
Debt 1,0569,5693,254 2,1242,053
Derivative instruments and hedges, liabilities 199     
Deferred revenue and credits395510814
Contract with customer, liability1,658
Other liabilities 790 300540  
Other undisclosed current liabilities5,0575,0835,7736,70826,2953,9984,000
Total current liabilities:18,73116,94521,11818,11732,12410,34912,398
Noncurrent Liabilities
Long-term debt and lease obligation37,96013,0526,19715,77918,47711,8797,418
Long-term debt, excluding current maturities37,96012,7166,19715,77918,47711,8797,418
Operating lease, liability 336 
Liabilities, other than long-term debt2,7801,6218,43921,26640,1386,9803,499
Deferred revenue and credits1,3021,6972,881
Deferred revenue 5782,552
Contract with customer, liability3,802
Other liabilities2,7801,0437907901,090690618
Derivative instruments and hedges, liabilities  5,09716,67437,7464,593 
Other undisclosed noncurrent liabilities    222  
Total noncurrent liabilities:40,74014,67314,63637,04558,83718,85910,917
Total liabilities:59,47131,61835,75455,16290,96129,20823,315
Stockholders' equity
Stockholders' equity attributable to parent45,87035,29414,846(27,227)(40,763)(1,923)17,227
Common stock34271611261187658
Additional paid in capital720,386656,472600,306567,655546,092519,911512,201
Accumulated other comprehensive income (loss)(3)  1(4)6(3)
Accumulated deficit(674,547)(621,205)(585,621)(595,009)(586,969)(521,916)(495,029)
Total stockholders' equity:45,87035,29414,846(27,227)(40,763)(1,923)17,227
TOTAL LIABILITIES AND EQUITY:105,34166,91250,60027,93550,19827,28540,542

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues42,2956,01928,7955,4097,5792,51519,024
Cost of revenue
(Cost of Goods and Services Sold)
(4,737)      
Gross profit:37,5586,01928,7955,4097,5792,51519,024
Operating expenses(87,112)(44,896)(29,169)(30,766)(36,390)(31,908)(31,450)
Operating loss:(49,554)(38,877)(374)(25,357)(28,811)(29,393)(12,426)
Nonoperating income (expense)(3,788)3,2939,76220,028(36,113)2,607(2,575)
Interest and debt expense (1,605)(1,815)(2,191)(2,373)(1,949)(2,307)
Other undisclosed income from continuing operations before equity method investments, income taxes 1,6051,8152,1912,3731,949 
Income (loss) from continuing operations before income taxes:(53,342)(35,584)9,388(5,329)(64,924)(26,786)(17,308)
Income tax expense    (101)(101) 
Net income (loss):(53,342)(35,584)9,388(5,329)(65,025)(26,887)(17,308)
Other undisclosed net income attributable to parent      2,307
Net income (loss) available to common stockholders, basic:(53,342)(35,584)9,388(5,329)(65,025)(26,887)(15,001)
Dilutive securities, effect on basic earnings per share   (19,919)   
Net income (loss) available to common stockholders, diluted:(53,342)(35,584)9,388(25,248)(65,025)(26,887)(15,001)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net income (loss):(53,342)(35,584)9,388(5,329)(65,025)(26,887)(17,308)
Comprehensive income (loss):(53,342)(35,584)9,388(5,329)(65,025)(26,887)(17,308)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(3) (1)5(10)92,304
Comprehensive income (loss), net of tax, attributable to parent:(53,345)(35,584)9,387(5,324)(65,035)(26,878)(15,004)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: